The difference between Nivolumab and Pembrolizumab

Nivolumab and Pembrolizumab and Pembrolizumab are two immune checkpoint inhibitors used to treat certain types of cancer. Although they all belong to the same class of drugs, they have some differences in indications, research evidence, dosage and adverse reactions.

1. Genotypic indications: Nivolumab is suitable for a variety of tumors, including non-small cell lung cancer, melanoma, renal cell carcinoma, etc. Pembrolizumab is suitable for non-small cell lung cancer, melanoma and cervical cancer.

2. Research evidence: Both nivolumab and pembrolizumab have obtained positive research results in clinical trials of different cancer types. They are widely used in different treatment regimens and have been approved by many drug regulatory agencies.

3. Dosage and frequency: The dosage and frequency of nivolumab and pembrolizumab may vary depending on the condition and clinical guidelines. The doctor will determine the most appropriate dosage and dosage regimen based on the patient's specific situation.

4. Adverse reactions: Nivolumab and pembrolizumab also have some differences in adverse reactions. Common adverse reactions include fatigue, nausea, vomiting, rash, etc. However, specific adverse effects may vary based on individual differences.

The generic drug Nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around RMB 4,000. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.